SCH900062

SCH900062 is an investigational small molecule developed by Schering-Plough (now Merck & Co.) for the treatment of Alzheimer's disease and cognitive dysfunction. It functions as a histamine H3 receptor antagonist. The histamine H3 receptor is a G protein-coupled receptor primarily located in the central nervous system, where it acts as a presynaptic autoreceptor and heteroreceptor, regulating the release of histamine and other neurotransmitters such as acetylcholine, dopamine, and norepinephrine. By antagonizing these receptors, SCH900062 aims to increase the synaptic levels of these neurotransmitters, thereby enhancing cognitive processes such as memory and attention. The compound reached Phase I clinical development, where it was evaluated in a first-in-human study (NCT00511108) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers using single and multiple ascending doses. Development of the compound appears to have been discontinued following the acquisition of Schering-Plough by Merck.